Met-enkephalin improves metabolic syndrome in high fat diet challenged mice through promotion of adipose tissue browning

    loading  Checking for direct PDF access through Ovid


Obesity and its related metabolic disorders including insulin resistance and fatty liver become major public health concerns in both developed and developing countries. Brown adipose tissue (BAT), a critical organ of energy expenditure due to thermogenesis, has been considered as an attractive target for prevention or treatment of obesity and obesity related diseases. Previous studies indicate Met-enkephalin (MetEnk) has the potential on adipocyte browning, however, whether MetEnk displays the impact on adipocyte browning in vivo to improve obesity associated morbidities is still unclear. In the present study, we showed that MetEnk effectively prevented high fat diet (HFD) induced C57BL/6J mice weight gain, clearly enhanced glucose tolerance and insulin sensitivity, and dramatically reduced hepatic steatosis in HFD fed mice. Mechanically, MetEnk restored protein kinase A (PKA) signaling pathway in HFD challenged mice and promoted subcutaneous white adipose tissue (WAT) browning. Our study suggests that MetEnk can be considered as a potential therapeutic peptide for diet-induced obesity and metabolic disorders.HIGHLIGHTSMetEnk prevented HFD induced weight gain and hepatic steatosis of mice.MetEnk enhanced glucose tolerance and insulin sensitivity in HFD challenged mice.MetEnk restored PKA signaling pathway in HFD challenged mice.

    loading  Loading Related Articles